Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $5.21M rose 129.3% year over year, ahead of the +21.0% change in trailing-twelve-month research & development. Sequentially, it rose 47.9% from the prior quarter. Over 3 fiscal years it compounded at +38.5% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +129.3% holds above the trailing-twelve-month pace of +21.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 17.22M USD
- Year-over-year change
- +11.2%
- 4-year CAGR
- +48.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.22M | +11.2% |
| FY2024 | 2024-12-31 | 15.48M | +101.1% |
| FY2023 | 2023-12-31 | 7.7M | +18.9% |
| FY2022 | 2022-12-31 | 6.48M | +81.9% |
| FY2021 | 2021-12-31 | 3.56M | — |
Research & Development vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +21.0% is the 4th highest of 9, against a peer median of +8.0%.
- Over three fiscal years its annual growth of +38.5% compares with a peer median of +15.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $41.33M USD | -11.2% | -6.2% | 274.8% | |
| LTM Mar 2026 | $38.53M USD | -58.1% | — | 31.1% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $33.44M USD | +11.2% | +29.0% | 279.0% |
| LTM Mar 2026 | $32.45M USD | -22.6% | +7.0% | — | |
| LTM Mar 2026 | $32.14M USD | +45.7% | -7.4% | 428.8% | |
| LTM Mar 2026 | $21.18M USD | +82.5% | +30.2% | — | |
| LTM Mar 2026 | $20.26M USD | +102.3% | +57.1% | — | |
| LTM Mar 2026 | CA$19.63M CAD | +4.7% | +15.5% | — | |
| LTM Mar 2026 | $15.76M USD | +21.0% | +38.5% | — | |
| Peer median (excluding GLSI) | — | +8.0% | +15.5% | 276.9% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 3.61K | 3.61K | 3.61K | 3.61K | 1.78K |
| Gross Profit | (3.61K) | (3.61K) | (3.61K) | (3.61K) | (1.78K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 3.56M | 6.48M | 7.7M | 15.48M | 17.22M |
| Selling, General & Admin | 1.04M | 1.56M | 1.63M | 2.15M | 2.23M |
| Operating Expenses | 4.59M | 8.04M | 9.32M | 17.63M | 19.45M |
| Depreciation & Amortization | 3.61K | 3.61K | 3.61K | 3.61K | 1.78K |
| EBITDA | (4.57M) | (7.82M) | (8.89M) | (17.41M) | (19.36M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (4.6M) | (8.04M) | (9.33M) | (17.64M) | (19.45M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 27.37K | 215.02K | 436.06K | 223.01K | 89.7K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 27.37K | 215.02K | 436.06K | 223.01K | 89.7K |
| Income Before Tax | (4.57M) | (7.83M) | (8.89M) | (17.41M) | (19.36M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (4.57M) | (7.83M) | (8.89M) | (17.41M) | (19.36M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.35) | (0.61) | (0.69) | (1.21) | (1.43) |
| EPS (Diluted) | (0.35) | (0.61) | (0.69) | (1.21) | (1.43) |
| Weighted Avg Shares | 12.94M | 12.91M | 12.85M | 13.01M | 13.53M |
| Weighted Avg Shares (Diluted) | 12.94M | 12.91M | 12.85M | 13.01M | 13.53M |
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.